have agreed to end their alliance in fibrosis. Galapagos will receive a payment of $7.5 million for work completed in 2012. Galapagos regains worldwide rights to all fibrosis assays and the targets discovered in the alliance. The company received a total of approximately $20.8 million in upfront and milestone payments from Roche under the collaboration.
"We regret that Roche ended the alliance due to a strategic change, but the good news is that all assets have returned to Galapagos," said Onno van de Stolpe, chief executive officer of Galapagos. "Our plan is to find another partner to continue the search for compounds against these debilitating diseases."